Oculis Holding AG is a cash-burning biotechnology company below the minimum market cap threshold for investment, with 3 of 4 recent earnings misses and revenue declining 27%, though analysts project more than 229% upside from current levels based on the pipeline option value.
Thesis pillars
- Analyst Implied Pipeline Upside↓Deteriorating
- Cash Burn Quality Concerns→Stable
- Earnings Miss Pattern↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026· older than 90 days
Oculis Holding AG (OCS) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $7.63: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Below long-term trend.
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach... Read more
Sell if holding. Engine safety override at $7.63: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 59. Score 5.3/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Fails on death cross (50MA < 200MA). Suitability: speculative.
Recent developments
updated Nov 4, 2026Recent Developments — Oculis Holding AG
Latest news
- NEWS Oculis Holding AG Reports Third Quarter 2026 Financial Results — fiscal.ai Nov 4, 2026
- NEWS Oculis Holding Q3 EPS $(0.37) Beats $(0.49) Estimate, Sales $8.619K Miss $290.000K Estimate — benzinga Nov 3, 2026 neutral
- NEWS Oculis Appoints Björn Tackenberg as Chief Scientific Officer — fiscal.ai Nov 2, 2026 positive
- NEWS Oculis Announces Upcoming Presentations on Privosegtor and PIONEER Program — fiscal.ai Oct 29, 2026 neutral
- NEWS HC Wainwright & Co. Reiterates Buy on Oculis Holding, Maintains $39 Price Target — benzinga Oct 23, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-04T11:59:36Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $7.63: Quality below floor (1.9 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10. Specifically: Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 59. Prior stop was $7.10. Score 5.3/10, moderate confidence.
Resistance target: $8.66 (+13.5% upside). Prior stop was $7.10. Stop-loss: $7.10.
DATA_ISSUE: analyst_target_implausible (raw $37.43 vs price $7.63 — ratio 4.9×). Rejected, falling back to technical TP.; Quality below floor (1.9 < 4.0).
Oculis Holding AG trades at a P/E of N/A (forward -4.0). TrendMatrix value score: 5.0/10. Verdict: Sell.
15 analysts rate OCS, with a consensus score of 4.4/5. 10 analysts publish price targets averaging $37.
What does Oculis Holding AG do?Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic,...
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.